Wilson & Boucher Capital Management LLC Has $5.86 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Wilson & Boucher Capital Management LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,621 shares of the company’s stock after purchasing an additional 415 shares during the quarter. Novo Nordisk A/S makes up about 4.9% of Wilson & Boucher Capital Management LLC’s investment portfolio, making the stock its 3rd largest holding. Wilson & Boucher Capital Management LLC’s holdings in Novo Nordisk A/S were worth $5,857,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Linscomb & Williams Inc. boosted its holdings in shares of Novo Nordisk A/S by 11.9% during the fourth quarter. Linscomb & Williams Inc. now owns 6,489 shares of the company’s stock valued at $671,000 after acquiring an additional 689 shares during the period. Congress Wealth Management LLC DE boosted its holdings in shares of Novo Nordisk A/S by 20.1% during the fourth quarter. Congress Wealth Management LLC DE now owns 13,643 shares of the company’s stock valued at $1,412,000 after acquiring an additional 2,283 shares during the period. Advisory Services Network LLC boosted its holdings in shares of Novo Nordisk A/S by 50.8% during the fourth quarter. Advisory Services Network LLC now owns 55,552 shares of the company’s stock valued at $5,747,000 after acquiring an additional 18,708 shares during the period. Hoylecohen LLC boosted its holdings in shares of Novo Nordisk A/S by 11.1% during the fourth quarter. Hoylecohen LLC now owns 9,220 shares of the company’s stock valued at $954,000 after acquiring an additional 920 shares during the period. Finally, Orion Portfolio Solutions LLC boosted its holdings in shares of Novo Nordisk A/S by 44.3% during the fourth quarter. Orion Portfolio Solutions LLC now owns 310,087 shares of the company’s stock valued at $32,993,000 after acquiring an additional 95,176 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded up $0.47 during midday trading on Friday, hitting $136.04. The company’s stock had a trading volume of 2,845,222 shares, compared to its average volume of 4,075,833. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The stock’s 50-day moving average price is $128.21 and its 200-day moving average price is $116.55. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28. The company has a market capitalization of $610.48 billion, a PE ratio of 46.91, a price-to-earnings-growth ratio of 1.40 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The firm had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. Analysts anticipate that Novo Nordisk A/S will post 3.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.